Perinatal Hypophosphatasia in a Premature Infant

Abstract

A premature male infant was delivered at 32 weeks' gestation due to category-2 fetal tracing after preterm labor. The physical exam showed shortened and bowed long bones, with calvarium felt in small area of the head. Serum alkaline phosphatase was very low on admission. Extensive metaphyseal abnormalities, bowing of long bones, and poor ossification of all bones were noted on skeletal survey (radiography). Based on ultrasound evidence of “bowing” and long bone fractures at 26 weeks, amniocentesis was performed that later diagnosed hypophosphatasia by genetic testing while ruling out osteogenesis imperfecta. Although ventilated initially, the infant gradually improved with enzyme replacement therapy (ERT) and was extubated to noninvasive ventilation for 6 weeks. Following clinical deterioration with hypoxic respiratory failure secondary to sepsis at 4 months of age, he succumbed to severe pulmonary hypertension, likely secondary to chronic lung disease and prolonged ventilation. Early diagnosis allowed timely initiation of appropriate therapy. Radiological improvement with the therapy showed promising results in this rare disease. Despite specific novel therapy being available, variability in presentation dictates prognosis in this previously universally fatal condition. The potential unknown effects of ERT on pulmonary vascular remodeling need further investigation.

Keywords

hypophosphatasia - ossification - alkaline phosphatase

• References

• 1 Whyte MP, Wenkert D, Zhang F. Hypophosphatasia: natural history study of 101 affected children investigated at one research center. Bone 2016; 93: 125-138
• 2 Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 1994; 15 (04) 439-461
• 3 Silver MM, Vilos GA, Milne KJ. Pulmonary hypoplasia in neonatal hypophosphatasia. Pediatr Pathol 1988; 8 (05) 483-493
• 4 Offiah AC, Vockley J, Munns CF, Murotsuki J. Differential diagnosis of perinatal hypophosphatasia: radiologic perspectives. Pediatr Radiol 2019; 49 (01) 3-22
• 5 Hofmann CE, Harmatz P, Vockley J. , et al; ENB-010-10 Study Group. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab 2019; 104 (07) 2735-2747
• 6 Rathbun JC. Hypophosphatasia; a new developmental anomaly. Am J Dis Child 1948; 75 (06) 822-831
• 7 Weiss MJ, Cole DE, Ray K. , et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci U S A 1988; 85 (20) 7666-7669
• 8 Mornet E. Hypophosphatasia. Metabolism 2018; 82: 142-155
• 9 Mornet E. Hypophosphatasia. Orphanet J Rare Dis 2007; 2: 40-40
• 10 Baumgartner-Sigl S, Haberlandt E, Mumm S. , et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone 2007; 40 (06) 1655-1661
• 11 Nunes ML, Mugnol F, Bica I, Fiori RM. Pyridoxine-dependent seizures associated with hypophosphatasia in a newborn. J Child Neurol 2002; 17 (03) 222-224
• 12 Demirbilek H, Alanay Y, Alikaşifoğlu A. , et al. Hypophosphatasia presenting with pyridoxine-responsive seizures, hypercalcemia, and pseudotumor cerebri: case report. J Clin Res Pediatr Endocrinol 2012; 4 (01) 34-38
• 13 Shohat M, Rimoin DL, Gruber HE, Lachman RS. Perinatal lethal hypophosphatasia; clinical, radiologic and morphologic findings. Pediatr Radiol 1991; 21 (06) 421-427
• 14 Zankl A, Mornet E, Wong S. Specific ultrasonographic features of perinatal lethal hypophosphatasia. Am J Med Genet A 2008; 146A [phone]
• 15 Pauli RM, Modaff P, Sipes SL, Whyte MP. Mild hypophosphatasia mimicking severe osteogenesis imperfecta in utero: bent but not broken. Am J Med Genet 1999; 86 (05) 434-438
• 16 Rodriguez E, Bober MB, Davey L. , et al. Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy. Pediatr Pulmonol 2012; 47 (09) 917-922
• 17 Mochizuki H, Saito M, Michigami T. , et al. Severe hypercalcaemia and respiratory insufficiency associated with infantile hypophosphatasia caused by two novel mutations of the tissue-nonspecific alkaline phosphatase gene. Eur J Pediatr 2000; 159 (05) 375-379
• 18 Barcia JP, Strife CF, Langman CB. Infantile hypophosphatasia: treatment options to control hypercalcemia, hypercalciuria, and chronic bone demineralization. J Pediatr 1997; 130 (05) 825-828
• 19 Nakamura-Utsunomiya A, Okada S, Hara K. , et al. Clinical characteristics of perinatal lethal hypophosphatasia: a report of 6 cases. Clin Pediatr Endocrinol 2010; 19 (01) 7-13
• 20 Esmel-Vilomara R, Hernández S, Campos-Martorell A, González-Roca E, Yeste D, Castillo F. Hypophosphatasia: novel mutation associated with an atypical newborn presentation. J Clin Res Pediatr Endocrinol 2019
• 21 Whyte MP. Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res 2017; 32 (04) 667-675
• 22 Whyte MP, Greenberg CR, Salman NJ. , et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012; 366 (10) 904-913
• 23 Whyte MP, Rockman-Greenberg C, Ozono K. , et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab 2016; 101 (01) 334-342
• 24 Kishnani PS, Rush ET, Arundel P. , et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab 2017; 122 (1-2): 4-17
• 25 Gennero I, Conte-Auriol F, Salles JP. Laboratory diagnosis of hypophosphatasia. Arch Pediatr 2017; 24 (5S2): S57-S60